AGENDA RADIOTERAPIA

1er BEST OF ASTRO - COLOMBIA 2021 - 26 DE MARZO 2021
Módulo: Cáncer de Mama
EXPOSITORES
DR. GUILLERMO POTDEVIN
DRA. ZAYDA SÁNCHEZ

Abstract 19 First 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost Versus 3-D-Conformal Radiotherapy with Consecutive Boost for Breast Cancer Patients

Abstract 20 Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial

Abstract 21 Development and Internal Validation of an NTCP-Model for Acute Coronary Events after Breast Cancer Radiotherapy: First Results of the Medirad Brace Study

Abstract 22 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Epigallocatechin-Gallate in the Prevention of Radiation-Induced Dermatitis

Abstract 24 Patient reported experience with treatment modalities and safety of adjuvant breast radiotherapy- First results of the randomized HYPOSIB – study

Abstract 25 Defining the Optimal Dose for 3D-Conformal Accelerated Partial Breast Irradiation (APBI): 10-years Follow Up of a Dose-Escalation Trial

Abstract 49 Heterogeneity in Outcomes Among Women with Clinically Node-Positive Breast Cancer and Axillary Pathologic Complete Response: An Analysis of NSABP B18, B27, B40, and B41

Abstract 52 De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost?

Módulo: Cáncer Gastrointestinal
EXPOSITORES
DR. IVÁN BOBADILLA
DRA. ISABEL GIRALDO

Abstract 95 Nonoperative management versus surgery in patients with complete endoscopic response to neoadjuvant therapy for rectal cancer

Abstract 96 Complete clinical response after short-course radiation and sequential multi-agent chemotherapy for non-operative treatment of rectal adenocarcinoma

Abstract 174 A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer

Abstract 175 Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of A Prospective Biomarker Study

Abstract 1070 Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma

Abstract 1072 Relationship of Dose to Vascular Target Volumes and Local Failure in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemoradiation

Abstract 3321 Stereotactic Body Radiotherapy vs Transarterial Chemoembolisation in locally advanced hepatocellular carcinoma (HERACLES: HEpatocellular carcinoma stereotactic RAdiotherapy CLinical Efficacy Study)

 Dra. Nathalie González - CDD REP DOM - Radioterapia en Ca de mama triple negativo 
                                Simposio Astra Zeneca - Dra. Monika Blake - Hospital ABC México
                              Abordaje del Paciente con Cáncer de Próstata: 10 años de sobrevida
                                                           10:00 AM hora local de Colombia
     
         Simposio ROCOL Colombia - Dr. Amilcar Estrada Molina 
“Synchrony: Una nueva era del “Motion Management”
11:00 AM hora local de Colombia
         Simposio Astra Zeneca - Dra. Monika Blake - Hospital ABC México
Régimen PACIFIC: Redefiniendo el rol de radioterapia en cáncer de pulmón EIII no resecable
5:00 PM hora local de Colombia
Simposio EuroEtika - Dr. César Alturo - Centro Javeriano de Oncologia
Retos actuales en el manejo de complicaciones en cavidad oral y
Radiodermitis secundaria a Radioterapia
6:00 PM hora local de Colombia
 Dr. Curtis Miyamoto - Temple University Hospital, Estados Unidos
Mitos y realidades del Cáncer de Mama y los avances para combatirlo
Módulo: Hematología
EXPOSITORES
DR. SERGIO CAFFIERO
DRA. LINA ARBELAEZ

Abstract 243 Assessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy

Abstract 1050 An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?

Abstract 1054 Efficacy of Low Dose Radiotherapy in Head & Neck MALT Lymphoma

Abstract 1083 A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

Abstract 1104 Is Bridging Radiation (RT) Safe with B Cell Maturation Antigen–targeting Chimeric Antigenic Receptor T Cells (CART-BCMA) Therapy?

Abstract 1105 Bridging Radiotherapy before CAR-T for High Grade Lymphoma ― Feasibility and Efficacy

Abstract 1108 Effective Pain Control with Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients with Painful Osseous Lesions

Abstract 1109 Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

Módulo: Cáncer Ginecológico
EXPOSITORAS
DRA. LINA LOAIZA
DRA. ELSA CUERVO

Abstract 2 Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): Final Analysis

Abstract 105 Is the Risk of Substantial LVSI in Stage I Endometrial Cancer Similar to PORTEC in the North American Population? - A Single Institution Study

Abstract 106 Utilizing Immune Profiles to Predict Pelvic Failure in Endometrial Cancer

Abstract 233 Elective inguinal node irradiation is not necessary in cervical cancer invading lower third of vagina

Abstract 234 Hyperthermia Combined with Concurrent Radiochemotherapy for 373 Patients with Cervical Cancer Stage IB-IV

Abstract 238 Assessment of Impact of Bone Marrow Sparing for Hematological and Gastrointestinal Toxicities in Cervical Cancer with External Beam Radiation Therapy

Abstract 3024 Prognostic Significance of Negative Conversion of High-Risk Human Papillomavirus DNA After Treatment in Cervical Cancer Patient

Módulo: Cáncer de Pulmón
EXPOSITORES
DR. ALEJANDRO GONZÁLEZ
DR. FRANZ USUGA

Abstract 3 RTOG0617 to externally validate blood cell ERCC1/2 genotypic signature as a radiosensitivity biomarker for both tumor and normal tissue for individualized dose prescription

Abstract 5 Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial

Abstract 147 Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Abstract 217 Randomized phase II trial of metformin in combination with chemoradiotherapy (CRT) in locally advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464)

Abstract 219 Individualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601

Abstract 220 A Phase III Randomized Trial of Palliative Radiation for Advanced Central Lung Tumours with Intentional Avoidance of the Esophagus (PROACTIVE)

Abstract 1044 Assessment of Coronary Artery Calcification Burden as a Risk Factor for Cardiac Toxicity in Patients Treated on Radiation Dose-escalation Trials for Stage III Non-small-cell Lung Cancer

Abstract 1045 Statin Use and Major Adverse Cardiac Events among High Cardiac Risk Patients with Lung Cancer Receiving Radiotherapy

Abstract LBA3 Patterns of Disease Progression After Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC

Abstract LBA8 Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia

Módulo: Cáncer de Cabeza y Cuello
EXPOSITORES
DR. JAVIER CIFUENTES
DR. EDUARDO GUERRERO

Abstract 178 Risk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors treated with definitive radiotherapy: A Retrospective Cohort Study among 1,988 Survivors

Abstract 179 Development of Advanced Preselection Tools to Reduce Unnecessary Plan Comparisons in Model-Based Selection of Head and Neck Cancer Patients for Proton Therapy

Abstract 181 Defining Radiotherapy (RT) Coverage for Non-Melanoma Skin Cancer (NMSC) Using Mohs Micrographic Surgery (MMS) Margins

Abstract 222 Nivolumab and ipilimumab combined with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: in-field toxicity analysis of a phase I clinical trial

Abstract 224 Results of a randomized, open label, multicenter trial assessing the safety, dose and schedule of RRx-001 (R001) in reducing severe oral mucositis (SOM) in patients receiving chemoradiation (CRT) for oral cavity/oropharynx squamous cell carcinoma (OSCC)

Abstract 226 Efficacy and Safety of Aprepitant for the Prevention of Nausea and Emesis during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC): A Phase 2 Trial

Módulo: Sistema Nervioso Central
EXPOSITORES
DR. RICARDO CENDALES
DR. AURELIO ANGULO MOSQUERA

Abstract 39 Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Tria

Abstract 40 A phase 2 study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with concomitant and adjuvant Metformin and Temozolomide (TMZ) in patients with Glioblastoma

Abstract 41 Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial

Abstract 42 Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001

Abstract 1124 Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib

Abstract 1155 Timing of Adjuvant Radiotherapy in Atypical Meningiomas

Abstract 1156 Prospective Evaluation of Microscopic Extension using Macropathology in Glioma Patients: Determination of Optimal Clinical Target Volume Margins for Radiotherapy

Abstract 1159 Biomarkers of Post-radiation Cerebellar Injury Are Associated with Neurocognitive Decline in Primary Brain Tumor Patients

Módulo: Cáncer Genitourinario
EXPOSITORES
DR. JUAN CARLOS GALVIS
DRA. ILSE VÁSQUEZ

Abstract 4 Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG -0526

Abstract 32 Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

Abstract 35 Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

Abstract 54 STEREOTACTIC RADIOTHERAPY FOR OLIGOPROGRESSION IN METASTATIC KIDNEY CANCER PATIENTS RECEIVING TYROSINE KINASE INHIBITOR THERAPY: A PROSPECTIVE PHASE II MULTI-CENTRE STUDY

Abstract 55 Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial

Abstract 126 Five-Year Toxicity After EBRT For Localized Prostate Cancer With or Without a Simultaneously Integrated Focal Boost up to 95Gy: Results of a Randomized Controlled Trial

Abstract 127 An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

Abstract 128 An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

Abstract LBA1 Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer

Módulo: Radioterapia Paliativa
EXPOSITORES
    DRA. ERIKA GALLEGOS
DRA. LINA CORRALES

Abstract 67 The Impact of Provider-Driven Serious Illness Conversations on Length of Palliative Radiotherapy for Bone Metastases

Abstract 68 Influence of the Pain Duration on Pain Outcomes Following Palliative Radiotherapy for Painful Tumors: The Sooner the Irradiation, the Better?

Abstract 69 External validation of the Bone Metastases Ensemble Trees for Survival (BMETS) machine learning model to improve estimation of life expectancy

Abstract 70 Classification of patients at imminent risk of death at the time of palliative radiotherapy consultation

Abstract 182 Phase II Clinical Trial of Stereotactic Body Radiotherapy for Painful Non-Spine Bone Metastases

Abstract 184 Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial

Abstract 185 Safety and efficacy of multi-site stereotactic body radiotherapy and pembrolizumab for patients with large, treatment-refractory tumors

Abstract LBA2 CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases

Abstract 95 Pilot Assessment of the BMET Decision Support Platform: A Tool to Improve Provider Survival Estimates and Selection of Prognosis-Appropriate Treatment for Patients with Symptomatic Bone Metastases

Abstract 96 Rapid Access Multidisciplinary Bone Metastases Clinic Decreases Financial Toxicity for Patients Undergoing Palliative Radiation

Abstract 98 A Prospective Randomized Phase II Trial of Single-Fraction versus Multi-Fraction Stereotactic Spine Radiosurgery for Spinal Metastases: An Initial Analysis

Abstract 99 Improving the Palliative Patient Journey in Radiation Oncology

Abstract 100 Single-Fraction Stereotactic versus Conventional Multifraction Radiation for Predominantly Non-Spine Bone Metastases: A Randomized Phase II Trial

Abstract 148 Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

Abstract 149 Pre-Treatment and Early Post-Radiotherapy PET Metabolic Metrics Predict Probability of Local Relapse in Oligometastases

Abstract 153 A Volumetric Dosimetry Analysis of Vertebral Body Fracture Risk after Spine Stereotactic Radiosurgery